GLP-1 Drugs and Sleep Apnea — A Breakthrough?

GLP-1 Drugs and Sleep Apnea — A Breakthrough? - 30 Million Americans Tired of Their CPAP

24 min · 7 de abr de 2026
Portada del episodio GLP-1 Drugs and Sleep Apnea — A Breakthrough? - 30 Million Americans Tired of Their CPAP

Descripción

Join host Julia Cartwright as she explores tirzepatide's groundbreaking FDA approval for obstructive sleep apnea in adults with obesity. We discuss clinical trials showing remarkable AHI reductions, why CPAP adherence fails millions, the drug's multi-pathway mechanisms, and what this pharmaceutical option means for personalized sleep medicine treatment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de GLP-1 Drugs and Sleep Apnea — A Breakthrough?!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

5 episodios

episode GLP-1 Drugs and Sleep Apnea — Uncover the breakthrough reshaping treatment with Julia Cartwright artwork

GLP-1 Drugs and Sleep Apnea — Uncover the breakthrough reshaping treatment with Julia Cartwright

Join Julia Cartwright as she explores the groundbreaking approval of GLP-1 drugs for sleep apnea treatment, a potential game-changer for thirty million Americans frustrated with traditional CPAP therapy. Discover the real science, patient outcomes, and what this breakthrough means for anyone seeking alternatives that actually work. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7 de abr de 202632 s
episode GLP-1 Drugs and Sleep Apnea — A Breakthrough? - 30 Million Americans Tired of Their CPAP artwork

GLP-1 Drugs and Sleep Apnea — A Breakthrough? - 30 Million Americans Tired of Their CPAP

Join host Julia Cartwright as she explores tirzepatide's groundbreaking FDA approval for obstructive sleep apnea in adults with obesity. We discuss clinical trials showing remarkable AHI reductions, why CPAP adherence fails millions, the drug's multi-pathway mechanisms, and what this pharmaceutical option means for personalized sleep medicine treatment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7 de abr de 202624 min
episode GLP-1 Drugs and Sleep Apnea — A Breakthrough? - Why Weight Loss Isn't the Whole Story artwork

GLP-1 Drugs and Sleep Apnea — A Breakthrough? - Why Weight Loss Isn't the Whole Story

Host Julia Cartwright explores groundbreaking research on GLP-1 drugs and sleep apnea, revealing how medications like tirzepatide work beyond weight loss through brain receptors, anti-inflammatory effects, and metabolic improvements. Drawing on SURMOUNT-OSA trials and emerging science, she explains why these multi-pathway treatments are revolutionizing our understanding of obstructive sleep apnea as a whole-body condition. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7 de abr de 202624 min
episode GLP-1 Drugs and Sleep Apnea — A Breakthrough? - Why Weight Loss Isn't the Whole Story artwork

GLP-1 Drugs and Sleep Apnea — A Breakthrough? - Why Weight Loss Isn't the Whole Story

Host Julia Cartwright explores groundbreaking research on GLP-1 drugs and sleep apnea, revealing how medications like tirzepatide work beyond weight loss through brain receptors, anti-inflammatory effects, and metabolic improvements. Drawing on SURMOUNT-OSA trials and emerging science, she explains why these multi-pathway treatments are revolutionizing our understanding of obstructive sleep apnea as a whole-body condition. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7 de abr de 202624 min
episode GLP-1 Drugs and Sleep Apnea — A Breakthrough? - The Trial That Changed Everything artwork

GLP-1 Drugs and Sleep Apnea — A Breakthrough? - The Trial That Changed Everything

Join Julia Cartwright as she explores the groundbreaking FDA approval of tirzepatide (Zepbound) for obstructive sleep apnea—the first medication ever approved for this condition. We dive into the SURMOUNT-OSA trials, examining how this weight-loss drug reduced breathing interruptions and eliminated symptoms in 50% of participants, offering new hope beyond CPAP. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7 de abr de 202623 min